drugset / Trial / NCT01623271

Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)

NCT01623271

Terminated 5 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if an FDA-approved drug (Gralise) can help people with certain types of neuropathic pain without causing too many side effects.

Timeline

Start
2013-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 1800 mg Oral